Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

us' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals, progress and expected timing of clinical studies, including the progress, timing and design of Phase 3 clinical development for Amigal, the progress and timing of the availability of data from the Phase 2 extension study of Amigal, the progress and timing of Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the timing of the release of data from the Phase 2 clinical trials for Plicera, the initiation of Phase 2 clinical development of AT2220 for the treatment of Pompe disease, and the possibility and timin
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 The 6th Annual ... held on October 29-30 in San Francisco, CA. This ... and government researchers and clinicians focused on addressing and ... , In the twelve years since the sequencing of ... been introduced with pharmacogenetic information in the label and ...
(Date:8/20/2014)... ear could improve the health of your heart, researchers ... Leeds used a standard TENS machine like those designed ... the tragus, the small raised flap at the front ... canal. , The stimulation changed the influence of the ... signals that can drive failing hearts too hard. , ...
(Date:8/19/2014)... One of the major limitations in ... vascular supply. Nutrient and gas transport throughout synthetic ... for successful regeneration and integration into the patient’s ... vascularization and promote angiogenesis in a variety of ... and architecture, and enhancing scaffolds with stem cells. ...
(Date:8/19/2014)... DANVILLE, Pa. , Aug. 19, 2014 ... C has been nominated for a Centers for Disease ... to addressing a major public health concern. ... Health System, is one of a team of researchers ... (CDC) Charles C. Shepard Science Award for Data Methods ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Haven, Conn.A team led by Yale University researchers has ... step toward the ultimate dream of building a quantum ... chip to successfully run elementary algorithms, such as a ... device for the first time. Their findings will appear ...
... run 30-second spot on Pyratine XR(TM) and Rosacea - , ... Bulletin Board: SNKTY), a Life Sciences company engaged in the ... announced today that on June 27, 2009 at 7:19 AM ... tetrahydropyranyl adenine) and rosacea, a condition afflicting more than 14 ...
... N.C., June 26 Syngenta Biotechnology, Inc. announced today ... Evogene, Ltd., focusing on identifying plant genes related to ... exclusive licensing rights to candidate genes discovered by Evogene ... is a soil parasite which attacks the roots of ...
Cached Biology Technology:Scientists create first electronic quantum processor 2Television News Segment Featuring Pyratine XR to Air to 18 Million + Households on DIRECTV NewsCluster 2Syngenta and Evogene to Collaborate on Soybean Nematode Resistance 2
(Date:8/21/2014)... pancreatitis involves the pancreas digesting itself resulting in severe ... the UK around 20,000 patients are diagnosed with the ... cure and treatment is restricted to intravenous fluid and ... Faculty of Life Sciences, who led the research, said ... from gall stones and excessive alcohol intake combined with ...
(Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
(Date:8/20/2014)... the University of Tbingen, Arizona State University, the Wellcome ... Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... 1000 years old. The pathogen is a relative of ... causes disease in humans today. These researchers assume that ... coast. "The link to sea lions was unexpected" comments ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... - University of Kansas scientists have found that infants ... acids (LCPUFA) from birth to 12 months scored significantly ... intelligence conducted between the ages of three to six ... on detailed tasks involving pattern discrimination, rule-learning and inhibition ...
... Ill. A successful program that increased the number ... consumption by 50 percent among Latino children had two ... "First, we got mothers and other relatives ... for Latinos. Many programs, delivered at school, target only ...
... Colorado Cancer Center member recently published in the journal ... young, female cancer survivors, quality of life is significantly ... survivors to 66 healthy controls and found that, as ... the general population. Of note, survivors reported particular stress ...
Cached Biology News:DHA-enriched formula in infancy linked to positive cognitive outcomes in childhood 2Latino families in study eat more fruits and veggies, drink less soda 2Latino families in study eat more fruits and veggies, drink less soda 3Perception of fertility affects quality of life in young, female cancer survivors 2
... Chemicon Select Tissue Arrays are intended for ... tissues were fixed in neutral buffered formalin ... and diagnosis was performed by certified pathologists. ... paraffin blocks and relocated into a new ...
... adult normal Mega Western Protein Array was ... Mega Western Protein Arrays are manufactured using ... tissue sources. A protein sample from each ... with a Protein molecular weight marker on ...
... Proteomic Imaging System, Professional Package Superior ... Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... system for both proteomic and general life ... flexibility, enabling the use of all dyes ...
... single use spatulas have been designed to ... are for those interested in eliminating the ... Each spatula is individually packaged, RNase/DNase free, ... is a new product number, created to ...
Biology Products: